AR antagonist 7
AR antagonist 7 (86) is an androgen receptor (AR) antagonist that can be used in the research of hair loss.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 876759-97-6
- Formule: C16H12F3NO2
- Masse moléculaire:307.27
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MDA-MB-231 | IC50 |
299 nM
Compound: 6l
|
Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response
Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response
|
[PMID: 19286380] |
| Sf9 | IC50 |
69 nM
Compound: 6l
|
Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system
Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system
|
[PMID: 19286380] |
Chemical Information
-
CAS No. 876759-97-6
-
Masse moléculaire 307.27
-
Formule C16H12F3NO2
-
SMILES
N#CC1=CC=C(OC2=CC=C(C)C=C2OC)C=C1C(F)(F)F
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
AR antagonist 7 Related Classifications
HY-160692 Related Classifications
Powered by Bioz